It also implies that a user can take their dose at any time of day, regardless of their desired health outcome
It is important to emphasise that these proposals are based almost entirely on preclinical data principally in vitro (cell culture) experiments and animal studies and have not been reliably demonstrated in robust human clinical trials: Stimulation of follicle enlargement: Laboratory studies suggest GHK-Cu may increase hair follicle size, potentially counteracting the miniaturisation associated with androgenetic alopecia (pattern hair loss), though this has not been confirmed in humans
Cathelicidin attenuates hyperoxia-induced kidney injury in newborn rats
Developing portal hypertension as well as established portal hypertension were both rapidly counteracted in BDL rats (i.e., BPC 157 per-orally, in drinking water, since the end of week 4) (Sever et al., 2019)
there are no completed controlled human trials of injectable GHK-Cu , and injectable GHK-Cu is an unapproved research chemical presented for research and educational use only
